Lord’s Mark Industries has received UK regulatory approval for its diagnostics portfolio, targeting a December 2026 commercial launch. The company plans to open a UK pathology lab in January 2027 while targeting revenue of ₹1,550 crore for FY2027. Investors are also watching the upcoming demerger of its renewable energy unit.
Lord’s Mark Industries has secured registration from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its In-Vitro Diagnostics (IVD) portfolio. This approval, finalized on September 24, 2026, allows the company to market various clinical devices in the UK, including haematological cell analysers, clinical chemistry analysers, and associated cleaning agents. This development follows the company’s previous regulatory win for its Renalyx haemodialysis system, marking a significant step in its international expansion strategy.
The company is now working to transition from an exporter of medical technology to an integrated healthcare provider. Management has advanced its commercial launch timeline in the UK to December 2026, two months earlier than previously projected. To support this service-oriented model, the firm is also preparing to establish a physical pathology laboratory in the UK, which is scheduled to commence operations in January 2027. By pairing hardware sales with local diagnostics services, the company intends to capture a larger share of the British medical sector.
From a financial and corporate perspective, the company is undergoing a period of restructuring. The board has proposed the demerger of its renewable energy and LED business into a separate entity named 'Lords Shakti Power Limited' by March 2027. This move is designed to simplify the company’s profile by separating the healthcare and energy verticals. For the current fiscal year, FY2027, the management has provided consolidated revenue guidance of ₹1,550 crore, with an estimated EBITDA margin of 20.8%.
Investors may note that the company’s path forward involves addressing specific operational and legacy challenges. The firm emerged from insolvency proceedings through a reverse merger finalized in 2025. Historically, the company has managed high debtor days, which remains a key factor for cash flow stability. The successful execution of international expansion and the completion of the proposed demerger are the primary operational tasks ahead. The market will likely watch how the company balances its healthcare service scaling with the complexities of its restructuring process.